Cargando…

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma

Uveal melanoma, the most common primary ocular malignancy in adults, carries a poor prognosis: 50% of patients develop the metastatic disease with a 10–25% 1-year survival and no established standard of care treatment. Prior studies of melphalan percutaneous hepatic perfusion (M-PHP) have shown prom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Modi, Sachin, Gibson, Tom, Vigneswaran, Ganesh, Patel, Shian, Wheater, Matthew, Karydis, Ioannis, Gupta, Sanjay, Takhar, Arjun, Pearce, Neil, Ottensmeier, Christian, Stedman, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles: Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893121/ https://www.ncbi.nlm.nih.gov/pubmed/35254333 http://dx.doi.org/10.1097/CMR.0000000000000806

Ejemplares similares

Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease
por: Karydis, Ioannis, et al.
Publicado: (2017)

Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience
por: Artzner, Christoph, et al.
Publicado: (2019)

Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review
por: Vogel, Arndt, et al.
Publicado: (2016)

Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma
por: Teal, Lindsey, et al.
Publicado: (2021)

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
por: Karydis, Ioannis, et al.
Publicado: (2016)

Prognostic Factors for Postoperative Bleeding Complications and Prolonged Intensive Care after Percutaneous Hepatic Chemosaturation Procedures with Melphalan
por: Struck, Manuel Florian, et al.
Publicado: (2023)

Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma
por: Schönfeld, Leon, et al.
Publicado: (2020)

Initiation of Chemosaturation With Percutaneous Hepatic Perfusion Program in Interventional Radiology Department
por: Öcal, Osman, et al.
Publicado: (2021)

Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study
por: Kolb, Manuel, et al.
Publicado: (2023)

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
por: Brüning, R., et al.
Publicado: (2020)

Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery
por: Dewald, C. L. A., et al.
Publicado: (2020)

Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience
por: Dewald, Cornelia L. A., et al.
Publicado: (2021)

New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option
por: Dewald, Cornelia L. A., et al.
Publicado: (2022)

Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
por: Tong, T. M. L., et al.
Publicado: (2022)

Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers
por: Veelken, Rhea, et al.
Publicado: (2021)

Radial Artery Access for Hepatic Chemosaturation: The First Description of Technical Feasibility
por: Frost, Joshua P, et al.
Publicado: (2021)

Anästhesiologisches und postinterventionelles Management bei perkutaner hepatischer Melphalanperfusion (Chemosaturation)
por: Kliem, Peter, et al.
Publicado: (2022)

ASO Author Reflections: Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Hepatic Metastases from Ocular Melanoma
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer
por: Meijer, T. Susanna, et al.
Publicado: (2022)

Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery
por: Struck, Manuel Florian, et al.
Publicado: (2021)

Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases
por: Bethlehem, Martijn S., et al.
Publicado: (2021)

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial)
por: Olofsson Bagge, Roger, et al.
Publicado: (2023)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.
por: Borel Rinkes, I. H., et al.
Publicado: (1997)

Successful use of adalimumab in immune checkpoint inhibitor-associated inflammatory arthritis
por: Oke, Anuoluwapo R, et al.
Publicado: (2018)

Evaluation of Delcath Systems’ Generation 2 (GEN 2) Melphalan Hemofiltration System in a Porcine Model of Percutaneous Hepatic Perfusion
por: Moeslein, Fred M., et al.
Publicado: (2014)

Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
por: Guadagni, Stefano, et al.
Publicado: (2017)

Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
por: Meijer, T. Susanna, et al.
Publicado: (2020)

Isolated Limb Perfusion with Melphalan and TNF-α in the Treatment of Extremity Sarcoma
por: Verhoef, Cornelis, et al.
Publicado: (2007)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018)

Analysis of patient’s X-ray exposure in hepatic chemosaturation procedures: a single center experience
por: Ebel, Sebastian, et al.
Publicado: (2022)

Isolated Hepatic Perfusion with 200 mg Melphalan for Advanced Noncolorectal Liver Metastases
por: van Iersel, Liselot B. J., et al.
Publicado: (2008)

The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.
por: Wu, Z. Y., et al.
Publicado: (1997)

Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

Thrombotischer Verschluss der extrakorporalen Zirkulation während hepatischer Chemosaturation trotz zielgerechter Antikoagulation: Ein Fallbericht
por: Kuhner, M., et al.
Publicado: (2022)

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
por: Klaase, J. M., et al.
Publicado: (1994)

Erratum to: Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
por: de Leede, Eleonora M., et al.
Publicado: (2017)

Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
por: Wilt, J H W de, et al.
Publicado: (1999)

Percutaneous Exposure Incidents of the Health Care Personnel in a Newly Founded Tertiary Hospital: A Prospective Study
por: Falagas, Matthew E., et al.
Publicado: (2007)

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
por: de Wilt, J H W, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_lfk3vjhgo5italrr0rvddgeua3